Biophytis Announces Successful Industrial Transfer of BIO101 Production by Seqens

Paris and Cambridge, June 12, 2024 – Biophytis SA, a clinical-stage biotechnology company focused on age-related diseases, has announced the successful industrial-scale transfer of BIO101 (20-hydroxyecdysone) production by Seqens. Seqens has produced the first GMP-compliant batch at its Villeneuve La Garenne plant.

This batch is set to be used in Biophytis' clinical program for treating respiratory deterioration in Duchenne Muscular Dystrophy (DMD) patients. DMD is a rare genetic disorder leading to severe muscle degeneration. BIO101 shows potential in improving respiratory capacity and quality of life for non-ambulatory patients in advanced stages of DMD.

Biophytis CEO, Stanislas Veillet, stated that this step reinforces their capability to offer unique therapeutic solutions and accelerates the launch of clinical programs. Biophytis is seeking partners and funding to initiate a phase 1-2 clinical trial to evaluate BIO101’s pharmacokinetics, safety, and efficacy in DMD patients.